

## Biocatalysis

Zitierweise: *Angew. Chem. Int. Ed.* **2021**, *60*, 18673–18679

Internationale Ausgabe: doi.org/10.1002/anie.202104476

Deutsche Ausgabe: doi.org/10.1002/ange.202104476

# Multienzyme One-Pot Cascades Incorporating Methyltransferases for the Strategic Diversification of Tetrahydroisoquinoline Alkaloids

Fabiana Subrizi, Yu Wang, Benjamin Thair, Daniel Méndez-Sánchez, Rebecca Roddan, Max Cárdenas-Fernández, Jutta Siegrist, Michael Richter, Jennifer N. Andexer, John M. Ward and Helen C. Hailes\*

**Abstract:** The tetrahydroisoquinoline (THIQ) ring system is present in a large variety of structurally diverse natural products exhibiting a wide range of biological activities. Routes to mimic the biosynthetic pathways to such alkaloids, by building cascade reactions *in vitro*, represents a successful strategy and can offer better stereoselectivities than traditional synthetic methods. *S*-Adenosylmethionine (SAM)-dependent methyltransferases are crucial in the biosynthesis and diversification of THIQs; however, their application is often limited *in vitro* by the high cost of SAM and low substrate scope. In this study, we describe the use of methyltransferases *in vitro* in multi-enzyme cascades, including for the generation of SAM *in situ*. Up to seven enzymes were used for the regioselective diversification of natural and non-natural THIQs on an enzymatic preparative scale. Regioselectivities of the methyltransferases were dependent on the group at C-1 and presence of fluorine in the THIQs. An interesting dual activity was also discovered for the catechol methyltransferases used, which were found to be able to regioselectively methylate two different catechols in a single molecule.

## Introduction

THIQs are an important group of bioactive alkaloids. Alongside their applications as analgesics and antitussives,<sup>[1–4]</sup> THIQs show promise as therapeutics towards cancer, neuro-pathologies and multi-drug resistant bacteria.<sup>[3,5–8]</sup> However, supply of these compounds for studies and clinical use is limited. Natural THIQs can be harvested from mixtures from certain plants, but their chemical syntheses are complicated by the presence of chiral centres and the density of functional groups.<sup>[9]</sup> An enzyme of particular interest has been norco-claurine synthase (NCS), which catalyses a Pictet–Spengler (PS) reaction between dopamine and 4-hydroxyphenylacetaldehyde, to initiate benzyloisoquinoline alkaloid (BIA)

biosynthesis. Most usefully, using natural and engineered NCS variants,<sup>[10–12]</sup> the  $\beta$ -arylethylamine and carbonyl substrates can be varied to generate a number of natural and non-natural THIQs.<sup>[13–16]</sup> The diversity of THIQs generated has been further extended by forming *in vitro* cascades with enzymes upstream of NCS.<sup>[17]</sup> In plant BIA biosynthesis, methyltransferase (MT) enzymes operate downstream of NCS to methylate norco-claurine.<sup>[18]</sup> Such natural product methylations involve transfer of a methyl group from *S*-adenosylmethionine (SAM) to specific nucleophilic sites on the scaffold, and is widely associated with activation of the compound or improvement of its biological properties.<sup>[19–24]</sup>

MTs are therefore an essential addition for the diversification of THIQs. However, while the *O*-MTs involved in producing natural BIAs are regioselective,<sup>[25,26]</sup> they lack the substrate scope *in vivo* needed to be components of a flexible enzyme cascade to larger sets of THIQs. While *in vitro* biocatalytic cascades take inspiration directly from natural biosynthetic pathways, they allow more flexibility over reaction design, offering control in the order and quantity of enzymes added to the cascade as well as the enzyme used. Importantly, the *in vitro* approach reduces background reactions such as the phosphate catalysed PS,<sup>[27]</sup> and can simplify product isolation and purification. Here we present the use of three *O*-MTs *in vitro*, catechol-*O*-MTs from *Rattus norvegicus* (*RnCOMT*),<sup>[28]</sup> *Coptis japonica* (*Cj-6-OMT*),<sup>[25,29]</sup> and *Myxococcus xanthus* (*MxSafC*),<sup>[30]</sup> and an *N*-MT from *Coptis japonica* (*CjCNMT*),<sup>[31]</sup> to establish potential reactivities towards a range of THIQs. We report the integration of these enzymes into up to 7-step cascades for the strategic diversification of bioactive compounds (Figure 1). The cost of SAM has also previously limited the scale of MT-catalysed reactions, but this challenge is resolved with the incorporation of a reported modular *in vitro* cofactor supply system,<sup>[32]</sup>

[\*] Dr. F. Subrizi, Dr. Y. Wang, B. Thair, Dr. D. Méndez-Sánchez,

Dr. R. Roddan, Prof. H. C. Hailes  
Department of Chemistry, University College London  
20 Gordon Street, London WC1H 0AJ (UK)  
E-Mail: h.c.hailes@ucl.ac.uk

Dr. M. Cárdenas-Fernández, Prof. J. M. Ward  
Department of Biochemical Engineering, University College London  
Bernard Katz Building, London WC1E 6BT (UK)


Dr. J. Siegrist, Prof. J. N. Andexer  
Institute of Pharmaceutical Sciences, University of Freiburg  
Albertstr. 25, 79104 Freiburg (Germany)

Dr. M. Richter

Fraunhofer Institute for Interfacial Engineering and Biotechnology  
(IGB), Branch Biocat  
Schulgasse 11a, 94315 Straubing (Germany)

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:  
<https://doi.org/10.1002/anie.202104476>.

© 2021 The Authors. Angewandte Chemie published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.




**Figure 1.** (a) Formation of THIQs using enzymes and *O*- or *N*-methylation using methyltransferases (MTs) and an *S*-adenosylmethionine (SAM) supply/*S*-adenosylhomocysteine (SAH) degradation system; (b) The route to biologically relevant methylated THIQs prepared in this work via cascades with up to 7-enzymes. Abbreviations: *E. coli* (*Ec*); methionine adenosyltransferase (MAT); methylthioadenosine nucleosidase (MTAN); L-methionine (L-Met); adenosine triphosphate (ATP); *S*-ribosyl-L-homocysteine (SRH).

demonstrating the capacity of such an approach in ambitious biocatalytic applications.

## Results and Discussion

### Initial *O*-MT Screening

In the initial screening, a variety of THIQs were prepared using *Thalictrum flavum* NCS (*Tf*NCS), in high enantiomeric excesses (*ees*) where the single isomer is indicated, and purified.<sup>[11,16,17]</sup> The substrate panel (Figure 2a) included BIAs (1–5) and C-1 substituted THIQs with linear aliphatic or cyclic moieties (6–11). BIAs lacking the catechol group on the isoquinoline scaffolds or those bearing a halide group (12–14) were also included. All substrates 1–14 were tested with MT enzymes *Rn*COMT and *Mx*SafC. *Cj*-6-OMT was also used for comparison as it is known to selectively methylate *in vivo* the 6-OH of norcoclaurine (*S*)-2.<sup>[29]</sup> Initially, purified enzymes were used for reactions with substrates 1–3. With the aim of scaling up the process and making it more viable in an industrial setting, the same reactions were also carried out with clarified lysates, showing regioselectivities that were comparable to the purified *O*-MTs (SI section 3.2). Clarified lysates were then used with all the substrates. We were delighted to see that all THIQs bearing a catechol were readily accepted and new peaks were detected by HPLC




**Figure 2.** Substrates used with the selected MTs indicated. (a) Structures of the THIQs tested. (b) Reaction conversions are based on the consumption of the THIQ analogues 1–14 used, by HPLC analysis against standard calibration curves. Reaction conditions: THIQ 0.5 mM, SAM 3 mM, and selected MTs (clarified lysate, 10% v/v) which showed conversions after 90 min: *Rn*COMT in blue, *Mx*SafC in purple, and *Cj*-6-OMT in pink. THIQs (R,S)-12, (S)-13, and (S)-14 were not accepted by any of the MTs tested and are not reported. All reactions were performed in duplicate. See SI for representative HPLC chromatograms and calibration curves.

within the first hour (Figure 2b and SI Figure S5). In general, *RnCOMT* and *MxSafC* showed broader substrate scope relative to *Cj*-6-OMT, with excellent activities towards THIQs with an aliphatic side chain (6–10), which were only slightly or not converted by *Cj*-6-OMT under these conditions. Notably, complete conversions were obtained within the first 90 min with substrates 1–11 with *RnCOMT*, while *MxSafC* showed some starting material left only in the case of substrates 9–11. As expected, none of the THIQs lacking a catechol moiety (12 and 14) were accepted by the MTs, including derivative 13 where a catecholic hydroxyl group was replaced with a bromine.

### Building the Enzyme Cascades and O-MT Regioselectivities

Establishment of the regiochemistries was also key, which required scale-up of the reactions for product characterisation. Several factors were considered. Firstly, the high cost of the cofactor SAM restricts its use in larger scale biocatalytic reactions in vitro: although it has been reported in the *N*-methylation of THIQs,<sup>[31]</sup> this is not practicable for wider applications. In previous work, integration of MTs into a linear cascade with two further enzymes overcame this issue using a methionine adenosyltransferase (MAT E.C. 2.5.1.6) and a methylthioadenosine nucleosidase (MTAN, E.C. 3.2.2.9).<sup>[33]</sup> MATs generate SAM from ATP and L-methionine, both of which are less expensive and importantly more stable than SAM. When SAM is used for the methylation reaction, *S*-adenosylhomocysteine (SAH) is formed as a by-product. SAH, which would otherwise inhibit the methylation, can then be cleaved by the MTAN into *S*-ribosyl-L-homocysteine (SRH) and adenine (Figure 1a). For the SAM supply/SAH degradation system, enzymes MAT and MTAN, both from *E. coli* (*EcMAT* and *EcMTAN*, respectively) were selected.<sup>[33]</sup> Secondly, clarified lysates were used instead of pure enzymes to avoid the requirement for enzyme purification steps. Thirdly, to further streamline the process, the methylation cascade reaction was coupled directly to the NCS-catalysed PS reaction in a one-pot, two-step cascade, obviating the need for purification of the THIQ intermediates. The methylation of representative substrates (*S*)-1, (*S*)-6, 9, 10 and (*S*)-11 was explored first (Scheme 1. *ees* for (*S*)-1 (> 97%) and (*S*)-6 (> 98%) are shown in the SI). Here it was essential that all the dopamine was consumed in the *Tf*NCS catalysed reaction before the MT step to avoid the methylation of unreacted dopamine,<sup>[33]</sup> which could interfere with the regiochemical outcome.

With the architecture of the cascades defined, a biocatalytic



**Scheme 1.** Four-enzyme cascades for the synthesis of: (a) THIQs (*S*)-6-OMe-1, (*S*)-6-OMe-6, and (*S*)-6-OMe-11, and (b) THIQs 6-OMe-9, 7-OMe-9, 6-OMe-10, and 7-OMe-10 from 9 and 10 respectively.

scale-up of the methylated THIQs was attempted in a single pot. Starting from dopamine (5–20 mM) and an excess of the corresponding carbonyl compound, the THIQs (*S*)-1, (*S*)-6, 9, 10 and (*S*)-11 were generated with high enantiopurity (for single isomer compounds) and the methylation step initiated by the addition of *RnCOMT* clarified lysate (10% v/v) in the presence of ATP, L-methionine and the SAM supply/SAH degradation system enzymes *EcMAT* (10% v/v) and *EcMTAN* (2.5% v/v). Using *RnCOMT* the methylated products (*S*)-6-OMe-1, (*S*)-6-OMe-6, 7-OMe-9, 7-OMe-10, and (*S*)-6-OMe-11 were isolated with good yields and high regioselectivities with only 5–10% of the opposite regioisomer detected by <sup>1</sup>H NMR spectroscopy in most cases (Table 1). As expected, the regiochemistry of the reaction was strongly dependent on the nature of the side chain, which directed the

**Table 1:** Isolated yields and regioisomeric ratios for the preparative scale cascade reactions described in Schemes 1–3.

Substrate	Product	MT	Yield <sup>[a]</sup>	Regioisomeric ratio <sup>[b]</sup> (6-OMe:7-OMe)
( <i>S</i> )-1	( <i>S</i> )-6-OMe-1	<i>RnCOMT</i>	55% (96%)	95:5
( <i>S</i> )-2	( <i>S</i> )-6-OMe-2	<i>RnCOMT</i>	55% (92%)	95:5
( <i>S</i> )-2	( <i>S</i> )-6-OMe-2	<i>MxSafC</i> <sup>[c]</sup>	43% (89%)	60:40
( <i>S</i> )-2	( <i>S</i> )-6,7-(OMe) <sub>2</sub> -2	<i>MxSafC</i> <sup>[c]</sup>	6% (9%) <sup>[d]</sup>	na
( <i>S</i> )-3	( <i>S</i> )-6,3'-(OMe) <sub>2</sub> -3	<i>RnCOMT</i>	34% (64%) <sup>[e]</sup>	95:5
( <i>S</i> )-3	( <i>S</i> )-6,4'-(OMe) <sub>2</sub> -3	<i>Cj</i> -6-OMT then <i>MxSafC</i>	27% (70%) <sup>[e]</sup>	100
( <i>S</i> )-5	( <i>S</i> )-6-OMe-5	<i>RnCOMT</i>	19% (27%)	95:5
( <i>S</i> )-5	( <i>S</i> )-6-OMe-5	<i>MxSafC</i>	20% (31%)	95:5
( <i>S</i> )-6	( <i>S</i> )-6-OMe-6	<i>RnCOMT</i>	44% (90%)	90:10
9	7-OMe-9	<i>RnCOMT</i>	40%	10:90
9	6-OMe-9	<i>MxSafC</i>	56% (94%) <sup>[f]</sup>	90:10
10	7-OMe-10	<i>RnCOMT</i>	45% <sup>[g]</sup> (90%)	10:90
10	6-OMe-10	<i>MxSafC</i>	30% <sup>[g]</sup> (89%)	90:10
( <i>S</i> )-11	( <i>S</i> )-6-OMe-11	<i>RnCOMT</i>	33% (40%)	85:15

[a] Isolated yield (yield by HPLC analysis against product standards in parenthesis); [b] 6-OMe:7-OMe calculated by NMR; [c] reaction with 2 equivalents of ATP and L-methionine; when an excess of methyl equivalents was used the dimethylated product (*S*)-6,7-(OMe)<sub>2</sub>-2 was observed; [d] the yield of (*S*)-6,7-(OMe)<sub>2</sub>-2 with 8 equiv of ATP and L-methionine was 28% (47%); [e] some impurities were detected by HPLC; [f] reaction on a pure sample of 9. When carried out in a cascade coupled with NCS the yield was 64% (not optimised); [g] reaction on a pure sample of 10.

methylation preferentially at the 6-OH for substrates (*S*)-**1**, (*S*)-**6**, and (*S*)-**11**, and surprisingly preferably on the 7-OH for substrates **9** and **10**. Interestingly, when **9** or **10** underwent the same reaction conditions with *MxSafC*, the 6-OH was methylated instead preferentially and derivatives 6-OMe-**9** or 6-OMe-**10** respectively were obtained in good yield and excellent regioselectivities (Table 1). This unique performance with a switch in the regioselectivities for both *RnCOMT* and *MxSafC* further confirms the complementarity of these two enzymes.<sup>[33]</sup>

With the challenge to demonstrate the potential of this approach, the methylation with *RnCOMT* was further coupled with a multistep *in vitro* enzyme cascade for the *in situ* generation of norcoclaurine (*S*)-**2** (generated in >97% *ee*) using *Candidatus Nitrosopumilus salaria* BD31 tyrosinase (*CnTYR*) and *Enterococcus faecalis* DC32 tyrosine decarboxylase (*EfTyrDC*), together with a versatile transaminase from *Chromobacterium violaceum*<sup>[34]</sup> (*CvTAm*) and wild-type *TfNCS* enzyme.<sup>[17]</sup> A total of seven enzymes as clarified cell lysates were used in the same pot, achieving the conversion of L-tyrosine into (*S*)-coclaurine (*S*)-**6-OMe-2** in a unique one-pot three step cascade (Scheme 2a).


The methylation with *RnCOMT* was almost completely regioselective with no appreciable regioisomeric peak detected by HPLC. When the cascade was scaled up to 50 mL (L-tyrosine 20 mM), (*S*)-**6-OMe-2** was isolated in 55% yield and small amounts (5% of total product) of the 7-*O*-methylated regioisomer were detected by <sup>1</sup>H NMR spectroscopy. The lower isolated yields compared to the complete conversion of the starting material and the almost quantitative yield measured by HPLC, reflects again the challenge of purifying such alkaloids.<sup>[35]</sup> Catechol *O*-MTs such as *RnCOMT* have not been shown to methylate adjacent

hydroxy groups or phenols, even in the presence of an excess of methyl equivalents. Interestingly, the structurally related *MxSafC*, proved to be an exception. This consideration derives from the fact that methylation of (*S*)-**2** with *MxSafC* and an excess of SAM, led to a regioisomeric mixture of (*S*)-**6-OMe-2** and (*S*)-**7-OMe-2** (ratio 60:40), which were converted over time into a third product. This unexpected product was isolated and characterized confirming the structure of the 6,7-dimethoxy tetrahydroisoquinoline (*S*)-**6,7-(OMe)<sub>2</sub>-2** (see the SI).


A one-pot cascade was also established for the synthesis and methylation of (*S*)-**5** (formed in 90% *ee*) (Scheme 2b). *CnTYR* and *EfTyrDC* were used for the hydroxylation and decarboxylation of 3-F-L-tyrosine,<sup>[17]</sup> then reaction with phenylacetaldehyde and *TfNCS* followed by methylation with *RnCOMT* on the crude reaction mixture, gave the 6-*O*-methylated derivative (*S*)-**6-OMe-5** which was isolated in 19% yield (27% HPLC yield) over the 7-enzyme steps. Similarly, using *MxSafC* gave (*S*)-**6-OMe-5** in 20% yield (31% HPLC yield). The limiting step is most likely the initial hydroxylation with *CnTYR*. The preferential methylation at the 6-OH position by both MTs is likely a consequence of substrate-active site interactions. However, the change in *MxSafC* regioselectivity between (*S*)-**1** and fluorinated (*S*)-**5** indicates electronic factors are also important. The fluorine adjacent to a catechol moiety decreases the p*K<sub>a</sub>* of the neighbouring -OH and has previously been shown to direct the methylation on the hydroxyl group to a position equivalent to that at 7-OH.<sup>[36]</sup> Here, the fluorine at C-8 in the THIQ scaffold directs the methylation unexpectedly towards (*S*)-**6-OMe-5** with *MxSafC*. Notably, *MxSafC* led to a mixture of the two regioisomeric products when (*S*)-**1**, lacking the fluorine, was used as starting material. We hypothesized that a subtle substrate conformational change together with an intramolecular hydrogen bonding between the fluorine and the adjacent -OH, can make methylation at that position more difficult.

### Extending the Enzyme Cascades for Further *O*- and *N*-methylations

A case of particular interest is norlaudanosoline (*S*)-**3**. This is a substrate for *Cj*-6-OMT and it is converted to the corresponding 6-*O*-methylated derivative (*S*)-**6-OMe-3**.<sup>[29]</sup> When the assay was performed with either *RnCOMT* or *MxSafC* and an excess of SAM, new product peaks not attributable to the 6- or 7-*O*-methylated products were identified by HPLC. Interestingly, when only one equivalent of SAM was used with *RnCOMT*, the peak corresponding to 6-*O*-methylated **3** was identified as the main product together with some starting material. If *MxSafC* was used instead, a mixture of two regioisomeric methylated products was identified (SI Figure S5). With the aim of elucidating the structure of the new products, a two-step, five-enzyme cascade was established for the synthesis and methylation of norlaudanosoline (*S*)-**3** (formed in >97% *ee*) in one pot (Scheme 3) starting from dopamine (20 mM). The wild-type *TfNCS* enzyme and *CvTAm*<sup>[34]</sup> were used in the first step,<sup>[37]</sup>




**Scheme 2.** (a) Seven-enzyme cascades for the synthesis of THIQs (*S*)-**6-OMe-2**, (*S*)-**7-OMe-2** and (*S*)-**6,7-(OMe)<sub>2</sub>-2** and (b) six-enzyme cascade for the synthesis of THIQs (*S*)-**6-OMe-5** on a laboratory preparative scale.



**Scheme 3.** Enzymes cascades for the synthesis of THIQs (*S*)-6,3'-(OMe)<sub>2</sub>-3, (*S*)-6,4'-(OMe)<sub>2</sub>-3, and (*S*)-7,4'-(OMe)<sub>2</sub>-3 on a laboratory preparative scale.

and the methylation step was then coupled and scaled up using *RnCOMT* together with the SAM supply/SAH degradation system. Product isolation confirmed that a second methylation occurred on the catechol moiety of the C-1 side chain and *RnCOMT* proved to be exceptionally selective, with methylation preferentially occurring at the 6-OH and the 3'-OH. Complete conversion into nororientaline (*S*)-6,3'-(OMe)<sub>2</sub>-3 was observed, which was isolated in 33% yield. This double methylation is completely unprecedented as it is known to be carried out by two different MTs in the BIA biosynthetic pathway, with *RnCOMT* combining the activity of a 6-OMT and a 3'-OMT.<sup>[38]</sup> *MxSafC* showed a similar performance, leading to a mixture of 6-OMe and 7-OMe-(*S*)-norlaudanosoline which were then converted into the corresponding dimethylated analogues (*S*)-norreticuline (*S*)-6,4'-(OMe)<sub>2</sub>-3 and (*S*)-norprotosinomenine<sup>[39]</sup> (*S*)-7,4'-(OMe)<sub>2</sub>-3 in the presence of an excess of methyl equivalents.<sup>[3]</sup> Although less selective, *MxSafC* could also combine the activity of two methyltransferases, including a 4'-OMT. This reactivity was used for the selective synthesis of (*S*)-norreticuline (*S*)-6,4'-(OMe)<sub>2</sub>-3 by coupling the *Cj*-6-OMT and the *MxSafC* in a one-pot three-step cascade (Scheme 3), highlighting the ability to mix and match MTs to directed products.

Finally, *N*-methylation of (*S*)-6-OMe-1 and (*S*)-6,3'-(OMe)<sub>2</sub>-3 (*S*)-nororientaline was also investigated for the total synthesis of (*S*)-2-NMe-6-OMe-1 and orientaline (*S*)-2-NMe-6,3'-(OMe)<sub>2</sub>-3 respectively (Scheme 4). *CjCNMT* is known to methylate coclaurine and several natural THIQs, including norlaudanosoline.<sup>[31,40,41]</sup> In a first attempt to synthesize the desired products, the *N*-methylation step was



**Scheme 4.** Synthesis of THIQs (*S*)-2-NMe-6-OMe-1 and (*S*)-2-NMe-6,3'-(OMe)<sub>2</sub>-3 on a laboratory preparative scale. (*S*)-1 and (*S*)-3 were formed in cascades starting from dopamine (see Schemes 1 and 3).

carried out in the same pot (in a cascade starting from dopamine), after completion of the *RnCOMT* step, by the addition of purified *CjCNMT* (methylation steps shown in Scheme 4). (*S*)-6,3'-(OMe)<sub>2</sub>-3 was converted in 16 hours and (*S*)-orientaline (*S*)-2-NMe-6,3'-(OMe)<sub>2</sub>-3 was isolated in 38% yield (overall from dopamine). Compound (*S*)-6-OMe-1 was also accepted by *CjCNMT* and converted into the corresponding *N*-methylated product (*S*)-2-NMe-6-OMe-1 with a 46% isolated yield (in a cascade starting from dopamine) and 66% yield by HPLC analysis. Notably, this SAM-dependent *N*-MT was shown to be active if coupled with the SAM supply/SAH degradation system. To our delight, the *CjCNMT* also showed comparable activity if added together with the *RnCOMT* in the same step, reducing reaction times; (*S*)-2-NMe-6-OMe-1 and (*S*)-orientaline (*S*)-2-NMe-6,3'-(OMe)<sub>2</sub>-3 were obtained in less than 48 hours in a two-step one-pot cascade from dopamine. In both cases traces (<5%) of the minor isomers (*S*)-2-NMe-7-(OMe)-1 and (*S*)-2-NMe-7,3'-(OMe)<sub>2</sub>-3, were noted.

Generally, *RnCOMT* is highly selective and the 6-OH is preferentially methylated except in the case of spiro-THIQs **9** and **10**, where a complete inversion of the selectivity was observed. To understand this pattern of regioselectivity, a selection of THIQs were docked into models of the *RnCOMT* and *MxSafC* active sites using AutoDock Vina.<sup>[42]</sup> The catechol-binding pocket forms a deep groove with the magnesium ion proximal to highly conserved lysine residues (K144 and K145 in *RnCOMT* and *MxSafC* respectively) involved in the deprotonation of the hydroxyl to be methylated. The catechol moiety coordinates with the magnesium ion, while the side chain establishes interactions in the outer region pointing either towards the so called „hydrophobic wall“ or towards the solvent,<sup>[35,43]</sup> defining the catechol position which is preferentially methylated. Nevertheless, none of our models could completely support the regioselectivity observed, presumably due to the high degree of reorientation of the active site around the specific substrate.<sup>[30]</sup> However, some docking analysis with (*S*)-6-OMe-3 and *RnCOMT* (which exhibited high regioselectivity for the second methylation at 3'-OH) and *MxSafC* (which favored the second methylation at 4'-OH) provided useful insights consistent with the experimental findings (SI Figure S6).

[\*] Due to the difficulty of isolating each component and the complexity of the NMR data, we cannot completely rule out the presence of the regioisomer at the 3'-OH position.

## Conclusion

In summary, we have developed in vitro enzymatic cascades for the synthesis of a wide range of methylated natural and non-natural THIQ alkaloids, starting from commercially available and inexpensive building blocks. The application of an efficient SAM supply/SAH degradation system, together with the use of clarified lysates coupled with the NCS step, contribute to make the scale-up of the whole process viable. Finally, methylated THIQ alkaloids in high enantiopurities such as (*S*)-norreticuline, (*S*)-coclaurine, (*S*)-nororientaline, and (*S*)-orientaline together with novel THIQs are readily available in high purity from a one-pot cascade. The methylation step showed exceptional regioselectivity bearing in mind there is a degree of non-enzymatic methylation (generally around 4%) which has also been reported in the literature.<sup>[30,44]</sup> An unprecedented dual activity has also been discovered for the methyltransferases *Rn*COMT and *Mx*SafC, which were found to be able to regioselectively methylate two different catechols in a single molecule. This unique activity permitted the regioselective synthesis of (*S*)-nororientaline in one single step from the precursor (*S*)-norlaudanosoline.

## Acknowledgements

The authors would like to thank the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/R021643/1) and 17-ERACoBioTech for financial support of this work to F.S. as part of the project BioDiMet: Methyl Transferases for the Functional Diversification of Bioactives. We also thank UCL (Dean's Prize) for funding to Y.W., Wellcome Trust (219857/Z/19/Z) funding for B.T., BBSRC (BB/N01877X/1) funding for D.M.-S and Birkbeck College, for a Birkbeck Anniversary PhD scholarship to R.R. Furthermore, we gratefully thank the UCL Mass Spectrometry and NMR Facilities in the Department of Chemistry UCL and 700 MHz NMR equipment support by EPSRC (EP/P020410/1). The recombinant production, purification and preparation of *Cj*CNMT by Christina Niedermayer and Patricia Huber (Fraunhofer IGB) is also greatly acknowledged.

## Conflict of Interest

The authors declare no conflict of interest.

**Stichwörter:** alkaloids · biocatalysis · methyltransferases · one-pot cascades · regioselectivity

- [1] C. Straube, S. Derry, K. C. Jackson, P. J. Wiffen, R. F. Bell, S. Strassels, S. Straube, *Cochrane Database Syst. Rev.* **2014**, 1–54.
- [2] H. Umihara, S. Yokoshima, M. Inoue, T. Fukuyama, *Chem. Eur. J.* **2017**, *23*, 6993–6995.
- [3] M. A. Altinoz, G. Topcu, A. Hacimuftuoglu, A. Ozpinar, A. Ozpinar, E. Hacker, İ. Elmaci, *Neurochem. Res.* **2019**, *44*, 1796–1806.

- [4] I. P. Singh, P. Shah, *Expert Opin. Ther. Pat.* **2017**, *27*, 17–36.
- [5] J. D. Guzman, T. Pesnot, D. A. Barrera, H. M. Davies, E. McMahon, D. Evangelopoulos, P. N. Mortazavi, T. Munshi, A. Maitra, E. D. Lamming, R. Angell, M. C. Gershater, J. M. Redmond, D. Needham, J. M. Ward, L. E. Cuca, H. C. Hailes, S. Bhakta, *J. Antimicrob. Chemother.* **2015**, *70*, 1691–1703.
- [6] M. Białoń, M. Żarnowska, L. Antkiewicz-Michaluk, A. Wąsik, *Psychopharmacology (Berl.)* **2020**, *237*, 1577–1593.
- [7] T. Xu, T. Kuang, H. Du, Q. Li, T. Feng, Y. Zhang, G. Fan, *Pharmacol. Res.* **2020**, *152*, 104632.
- [8] L. Braconi, G. Bartolucci, M. Contino, N. Chiamonte, R. Giampietro, D. Manetti, M. G. Perrone, M. N. Romanelli, N. A. Colabufo, C. Riganti, S. Dei, E. Teodori, *J. Enzyme Inhib. Med. Chem.* **2020**, *35*, 974–992.
- [9] F. Ghirga, M. Mori, A. Bonamore, L. Calisti, A. Boffi, A. Maccone, I. D'Acquarica, B. Botta, *Int. J. Mol. Sci.* **2017**, *18*, 2464.
- [10] B. R. Lichman, M. C. Gershater, E. D. Lamming, T. Pesnot, A. Sula, N. H. Keep, H. C. Hailes, J. M. Ward, *FEBS J.* **2015**, *282*, 1137–1151.
- [11] B. R. Lichman, J. Zhao, H. C. Hailes, J. M. Ward, *Nat. Commun.* **2017**, *8*, 14883.
- [12] R. Roddan, G. Gygli, A. Sula, D. Méndez-Sánchez, J. Pleiss, J. M. Ward, N. H. Keep, H. C. Hailes, *ACS Catal.* **2019**, *9*, 9640–9649.
- [13] B. M. Ruff, S. Bräse, S. E. O'Connor, *Tetrahedron Lett.* **2012**, *53*, 1071–1074.
- [14] J. J. Maresh, S. O. Crowe, A. A. Ralko, M. D. Aparece, C. M. Murphy, M. Krzeszowiec, M. W. Muldowney, *Tetrahedron Lett.* **2014**, *55*, 5047–5051.
- [15] M. Nishihachijo, Y. Hirai, S. Kawano, A. Nishiyama, H. Minami, T. Katayama, Y. Yasohara, F. Sato, H. Kumagai, *Biosci. Biotechnol. Biochem.* **2014**, *78*, 701–707.
- [16] J. Zhao, B. R. Lichman, J. M. Ward, H. C. Hailes, *Chem. Commun.* **2018**, *54*, 1323–1326.
- [17] Y. Wang, N. Tappertzhofen, D. Méndez-Sánchez, M. Bawn, B. Lyu, J. M. Ward, H. C. Hailes, *Angew. Chem. Int. Ed.* **2019**, *58*, 10120–10125; *Angew. Chem.* **2019**, *131*, 10226–10231.
- [18] T. Gurkok, E. Ozhuner, I. Parmaksiz, S. Özcan, M. Turktas, A. İpek, I. Demirtas, S. Okay, T. Unver, *Front. Plant Sci.* **2016**, *7*, 1–11.
- [19] G. Lunn, B. J. Banks, R. Crook, N. Feeder, A. Pettman, Y. Sabnis, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4608–4611.
- [20] M. Egbertson, G. B. McGaughey, S. M. Pitzemberger, S. R. Stauffer, C. A. Coburn, S. J. Stachel, W. Yang, J. C. Barrow, L. A. Neilson, M. McWherter, D. Perlow, B. Fahr, S. Munshi, T. J. Allison, K. Holloway, H. G. Selnick, Z. Yang, J. Swestock, A. J. Simon, S. Sankaranarayanan, D. Colussi, K. Tugusheva, M. T. Lai, B. Pietrak, S. Haugabook, L. Jin, I. W. Chen, M. Holahan, M. Stranieri-Michener, J. J. Cook, J. Vacca, S. L. Graham, *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4812–4819.
- [21] M. A. Walker, *Bioorg. Med. Chem. Lett.* **2017**, *27*, 5100–5108.
- [22] J. Claesen, M. Bibb, *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 16297–16302.
- [23] J. Lee, Y. Hao, P. M. Blair, J. O. Melby, V. Agarwal, B. J. Burkhart, S. K. Nair, D. A. Mitchell, *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 12954–12959.
- [24] L. Najmanová, E. Kutejová, J. Kadlec, M. Polan, J. Olšovská, O. Benada, J. Novotná, Z. Kameník, P. Halada, J. Bauer, J. Janata, *ChemBioChem* **2013**, *14*, 2259–2262.
- [25] F. Sato, T. Tsujita, Y. Katagiri, S. Yoshida, Y. Yamada, *Eur. J. Biochem.* **1994**, *225*, 125–131.
- [26] T. Frenzel, M. H. Zenk, *Phytochemistry* **1990**, *29*, 3505–3511.
- [27] T. Pesnot, M. C. Gershater, J. M. Ward, H. C. Hailes, *Chem. Commun.* **2011**, *47*, 3242–3244.
- [28] J. Vidgren, L. A. Svensson, A. Liljas, *Nature* **1994**, *368*, 354–358.
- [29] T. Morishige, T. Tsujita, Y. Yamada, F. Sato, *J. Biol. Chem.* **2000**, *275*, 23398–23405.

- [30] J. Siegrist, J. Netzer, S. Mordhorst, L. Karst, S. Gerhardt, O. Einsle, M. Richter, J. N. Andexer, *FEBS Lett.* **2017**, *591*, 312–321.
- [31] M. R. Bennett, M. L. Thompson, S. A. Shepherd, M. S. Dunstan, A. J. Herbert, D. R. M. Smith, V. A. Cronin, B. R. K. Menon, C. Levy, J. Micklefield, *Angew. Chem. Int. Ed.* **2018**, *57*, 10600–10604; *Angew. Chem.* **2018**, *130*, 10760–10764.
- [32] S. Mordhorst, J. Siegrist, M. Müller, M. Richter, J. N. Andexer, *Angew. Chem. Int. Ed.* **2017**, *56*, 4037–4041; *Angew. Chem.* **2017**, *129*, 4095–4099.
- [33] J. Siegrist, S. Aschwanden, S. Mordhorst, L. Thöny-Meyer, M. Richter, J. N. Andexer, *ChemBioChem* **2015**, *16*, 2576–2579.
- [34] U. Kaulmann, K. Smithies, M. E. B. Smith, H. C. Hailes, J. M. Ward, *Enzyme Microb. Technol.* **2007**, *41*, 628–637.
- [35] M. J. Vanden Eynden, K. Kunchithapatham, J. P. Stambuli, *J. Org. Chem.* **2010**, *75*, 8542–8549.
- [36] D. R. Thakker, C. Boehlerts, K. L. Kirks, R. Antkowiak, C. R. Creveling, *J. Biol. Chem.* **1986**, *261*, 178–184.
- [37] B. R. Lichman, E. D. Lamming, T. Pesnot, J. M. Smith, H. C. Hailes, J. M. Ward, *Green Chem.* **2015**, *17*, 852–855.
- [38] A. J. Vlietinck, T. De Bruyne, S. Apers, L. A. Pieters, *Planta Med.* **1998**, *64*, 97–109.
- [39] A. Ruiz-Olalla, M. A. Würdemann, M. J. Wanner, S. Ingemann, J. H. Van Maarseveen, H. Hiemstra, *J. Org. Chem.* **2015**, *80*, 5125–5132.
- [40] K. B. Choi, T. Morishige, F. Sato, *Phytochemistry* **2001**, *56*, 649–655.
- [41] K. B. Choi, T. Morishige, N. Shitan, K. Yazaki, F. Sato, *J. Biol. Chem.* **2002**, *277*, 830–835.
- [42] O. Trott, A. J. Olson, *J. Comput. Chem.* **2010**, *31*, 455–461.
- [43] B. J. C. Law, M. R. Bennett, M. L. Thompson, C. Levy, S. A. Shepherd, D. Leys, J. Micklefield, *Angew. Chem. Int. Ed.* **2016**, *55*, 2683–2687; *Angew. Chem.* **2016**, *128*, 2733–2737.
- [44] B. Rydberg, T. Lindahl, *EMBO J.* **1982**, *1*, 211–216.

Manuskript erhalten: 31. März 2021

Veränderte Fassung erhalten: 19. Mai 2021

Akzeptierte Fassung online: 8. Juni 2021

Endgültige Fassung online: 16. Juli 2021